Application of a new enzyme‐linked immunosorbent assay for detection of total hepatitis C virus core antigen in blood donors

Summary.  Recent studies have shown that total hepatitis C virus (HCV) core antigen, both free and antibody bound, is an accurate indirect marker of viral replication that can be used in clinical practice. The aim of the present study was to evaluate the performance of a new total HCV core antigen enzyme‐linked immunosorbent assay (ELISA) for detection and quantification of total core antigen in blood donors, testing positive for anti‐HCV antibodies and for prospective low‐risk population screening.A population comprising 257 samples, from blood donors detected reactive for anti‐HCV antibodies [137 recombinant immunoblot assay (RIBA) positive and 120 RIBA indeterminate], were tested by using a new total HCV core antigen ELISA. HCV‐RNA was quantified by using quantitative polymerase chain reaction (PCR) assays in all RIBA‐positive samples and RIBA‐indeterminate samples that were positive for the total core antigen. Specificity of the assay was studied in 1070 healthy blood donors negative for anti‐HCV antibodies.Compared with quantitative PCR assays, the total HCV core antigen assay showed 97·37% sensitivity. The three HCV‐RNA‐positive samples, which tested negative for the total core antigen, had a low viral load (<1·4 × 104 IU mL−1). All samples with more than 1·4 × 104 IU mL−1 of viral RNA were positive for total core antigen, independent of the HCV genotype. Concentration of total core antigen correlated significantly with those of HCV‐RNA (r = 0·614, P < 0·0001). Overall specificity in freshly collected blood donor specimens was 99·63%.Our data indicate that the total HCV core antigen ELISA has a sensitivity close to PCR assays in diagnosing HCV infection in blood donors with anti‐HCV antibodies and shows an excellent specificity in volunteer donors. This assay, in combination with anti‐HCV antibodies screening tests, could be an alternative to molecular assays for HCV infection screening in blood donors.